Correlation of Serum Tumor Markers CA153 CA125 Carcinoembryonic Antigen with Molecular Typing and Clinicopathological Characteristics in Patients with Stage I to III Invasive Breast Cancer before Treatment
GUO Jianhui, et al
The First Hospital of Hohhot, Inner Mongolia Hohhot, 010030,China
Abstract：Objective: To analyze retrospectively the correlation between serum tumor markers CA153, CA125 and CEA levels and molecular typing and clinicopathological features before treatment in patients with invasive breast cancer from I to III. Methods: 457 patients with stage I to III invasive breast cancer who visited the First Affiliated Hospital of Inner Mongolia Medical University from January 2016 to December 2020 were selected. The levels of serum CA153, CA125 and CEA before treatment were detected, and the clinical and pathological data were collected. (including the age of onset, tumor size, lymph node metastasis, clinical stage, histological grade, hormone receptor expression, HER-2 expression, Ki-67 expression, etc.), univariate analysis was used to analyze the correlation between the serological level of tumor markers and molecular subtypes and clinicopathological features, and multivariate analysis was used to analyze the independent risk factors related to each tumor marker. Results: Among 457 patients with stage I to III invasive breast cancer, 20 (4.38%), 34 (7.44%) and 25 (4.57%) of CEA, CA153 and CA125 serological levels were positive before treatment, respectively. Univariate analysis showed that there were significant differences in CEA and CA153 levels among different molecular subtypes (P <0.05). Serological levels of CEA, CA153 and CA125 were significantly increased in patients with tumor size ≥2cm with lymph node metastasis (N1) (P <0.05). The results of multivariate analysis showed that age (> 50 years old), tumor size (≥2cm), lymph node metastasis (N1) and HER-2(+) were all independent risk factors affecting the change of CEA level in breast cancer patients before treatment. Patients aged 50 years and older had a 4-fold increased risk of elevated CEA serological levels before treatment (OR=4.316, 95%CI: 2.262-9.443) compared with patients younger than 50 years old. Age (> 50 years old), tumor size (≥2cm) and lymph node metastasis (N1) were all independent risk factors affecting serum CA153 level changes in breast cancer patients before treatment (P <0.05), and the risk was about three times that of breast cancer patients under 50 years old (OR=3.685, 95%CI: 1.133-6.912,OR=3.331, 95%CI: 1.034-6.746). Lymph node metastasis (N1) and progesterone PR receptor (-) were independent risk factors for elevated CA125 serological levels in breast cancer patients before treatment (P <0.05). Conclusion: Age (> 50 years), tumor size (> 2cm) and lymph node metastasis (N1) are independent factors affecting the serological level of CEA and CA153 before treatment in patients with invasive breast cancer from I to III. Among the molecular typing results, HER-2 (+) independently can affecte the serum level of CEA, and progesterone PR receptor (-) independently affected the serum level of CA125.
郭剑辉, 王骞. Ⅰ~Ⅲ期浸润性乳腺癌患者治疗前血清肿瘤标志物与分子分型临床病理学特征的相关性研究[J]. 河北医学, 2021, 27(11): 1782-1790.
GUO Jianhui, et al. Correlation of Serum Tumor Markers CA153 CA125 Carcinoembryonic Antigen with Molecular Typing and Clinicopathological Characteristics in Patients with Stage I to III Invasive Breast Cancer before Treatment. HeBei Med, 2021, 27(11): 1782-1790.
[1] 李贺,郑荣寿,张思维,等.2014年中国女性乳腺癌发病与死亡分析[J].中华肿瘤杂志,2018,40(3):166~171. [2] Kaushal C,Bhat S,Koundal D,et al.Recent trends in computer assisted diagnosis (CAD) system for breast cancer diagnosis using histopathological images[J].Innovation & Research in Biomedical En,2019,40(4):211~227. [3] 王喆.乳腺癌血清肿瘤标志物与临床病理学特征的相关性研究[D].山东:山东大学,2019. [4] Sang E N,Lim W,J Jeong,et al.The prognostic significance of preoperative tumor marker (CEA,CA153) elevation in breast cancer patients:data from the korean breast cancer society registry[J].Breast Cancer Research and Treatment,2019,177(3):669~678. [5] M,Gion,P,et al.How tumor markers are used in the routine follow-up of breast and colorectal cancer.A survey of 29 italian hospitals[J].The International Journal of Biological Markers,2018,13(3):124~138. [6] Lee J S,Park S,Park J M,et al.Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer[J].Annals of Oncology,2013,24(5):1225~1231. [7] Wu S G,He Z Y,Zhou J,et al.Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer[J].Breast,2014,23(1):88~93. [8] Nam S E,Lim W,Jeong J,et al.The prognostic significance of preoperative tumor marker (CEA,CA15-3) elevation in breast cancer patients:data from the korean breast cancer society registry[J].Breast Cancer Research and Treatment,2019,177(3):669~678. [9] 黄亮亮,吕俊远,唐应麒,等.乳腺癌分子分型与临床病理特征的相关性研究[J].重庆医学,2019,48(10):1701~1704. [10] Al-Thoubaity F K.Molecular classification of breast cancer:a retrospective cohort study[J].Annals of Medicine and Surgery,2020,49:44~48.
2021, Vol. 27 
冀公网安备13080202000677号